TAG:
dna sequencing
Cleveland Clinic Lab Aims to Grow Reference Testing
CEO SUMMARY: In the national market for reference and esoteric testing, Cleveland Clinic Laboratories (CCL) is preparing to expand its presence. It has just moved into a $75 million state-of-the-art laboratory facility and wants to increase its outreach reference testing by four-fold with…
Roche Offers $5.7 Billion To Acquire Illumina Inc.
CEO SUMMARY: Once again, Roche is hunting for gene sequencing and gene analysis technology that can support its goal of being a world leader in gene-based therapeutics and clinical lab testing that utilizes gene tests and molecular diagnostics. Last week, Roche launched a hostile stock te…
Costs Falling Swiftly for Whole Genome Sequence
CEO SUMMARY: Several companies want to be first to achieve the holy grail in sequencing: an accurate whole human genome sequence produced in an hour for $1,000. Complete Genomics announced earlier this month that it could sequence the full human genome for a materials cost of $4,400 (not …
Molecular Advances Soon To Reshape Anatomic Path
CEO SUMMARY: Early this month, the second annual Molecular Summit assembled molecular first movers and early adopters to discuss their efforts to integrate molecular imaging and molecular diagnostics in patient care. One clear message emerged from two days of presentations and di…
Rapid Genome Sequencing Predicted by Mid-2009
CEO SUMMARY: In the same way that the Human Genome Project was disrupted by the entry of C. Craig Venter and Perkin-Elmer in what was then a 15-year, $3 billion project, now Complete Genetics of Mountain View, California, is disrupting the race to the $1,000 human genome sequence. Develop…
Bio-Reference Enters DNA Sequencing Market
CEOSUMMARY: Bio-Reference Laboratories has just placed an unexpected bet on the wide-open opportunities in genetic testing. The acquisition of GeneDX brings it a respected team of geneticists, capabilities in full DNA sequencing, and a proven track record in testing for rare and complex h…
Complete Human DNA Profiling as a STAT Test
MOST OF YOU ARE UNFAMILIAR WITH A NEW SCIENTIFIC PRIZE that is in the planning stage. On January 27, The Wall Street Journal published a story that disclosed the plans of the X Prize Foundation to award a prize, totaling between $5 million and $20 million, to the team that first deco…
Luminex and PerkinElmer Ink Licensing Agreement
CEO SUMMARY: PerkinElmer’s interest in the multiplex capabilities of Luminex’s xMap technology led to this new licensing agreement. PerkinElmer’s instrument systems played a major role in accelerating the work of the Human Genome Project. Now, besides bioresearch applications, Perki…
“November 5, 2001 Intelligence: Late Breaking Lab News”
It’s a milestone in the Pap smear testing marketplace. Cytyc Corporation, in its third quarter financial report, now claims its Thin-Prep® product has 51% of the national market for Pap testing. Estimates are that 55 million Pap tests are done annually in the United States. A 51% …
Washington G-2, AACC, Cerner, IBM, Visible Genetics, Bio-Reference Labs
LAB MEETINGS CONTINUE WITH STRONG ATTENDANCE DESPITE THE HASSLES that now come with cross-country travel, laboratorians throughout the United States continue to support industry meetings. Traditionally the largest lab meeting of the fall season, “Lab Institute 2001” expects good attenda…
CURRENT ISSUE
Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.